{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:28:23Z","timestamp":1790872103453,"version":"4.1.0"},"reference-count":50,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BST"],"published-print":{"date-parts":[[2025,8,31]]},"DOI":"10.5582\/bst.2025.01170","type":"journal-article","created":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T22:07:04Z","timestamp":1754258824000},"page":"468-478","source":"Crossref","is-referenced-by-count":1,"title":["Radiotherapy enhances triple therapy for conversion and survival in patients with unresectable hepatocellular carcinoma with portal vein tumor thrombus"],"prefix":"10.5582","volume":"19","author":[{"given":"Ying","family":"Zhou","sequence":"first","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghong","family":"Yao","sequence":"additional","affiliation":[{"name":"Chinese Evidence-based Medicine Center and CREAT Group, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianfu","family":"Wen","sequence":"additional","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Sung H, Ferlay J , Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians. 2021; 71:209-249.","DOI":"10.3322\/caac.21660"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Li B, Qiu J, Zheng Y, Shi Y, Zou R, He W, Yuan Y, Zhang Y, Wang C, Qiu Z, Li K, Zhong C, Yuan Y. Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma. Ann Surg Open. 2021; 2:e057.","DOI":"10.1097\/AS9.0000000000000057"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Liver EAftSot. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025; 82:315-374.","DOI":"10.1016\/j.jhep.2024.08.028"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Bi X, Zhao H, Zhao H, <i>et al<\/i>. Consensus of Chinese Experts on Neoadjuvant and Conversion Therapies for Hepatocellular Carcinoma: 2023 Update. Liver Cancer. 2025; 14:223-238.","DOI":"10.1159\/000541249"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Tang Z, Bai T, Wei T, Wang X, Chen J, Ye J, Li S, Wei M, Li X, Lin Y, Tang J, Li L, Wu F. TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study. BMC cancer. 2024; 24:717.","DOI":"10.1186\/s12885-024-12484-3"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Wu J, Wu J, Li S, Luo M, Zeng Z, Li Y, Fu Y, Li H, Liu D, Ou X, Lin Z, Wei S, Yan M. Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics. Bioscience trends. 2024; 18:42-48.","DOI":"10.5582\/bst.2023.01326"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Li J, Kong M, Yu G, Wang S, Shi Z, Han H, Lin Y, Shi J, Song J. Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma. Front Immunol. 2023; 14:1188308.","DOI":"10.3389\/fimmu.2023.1188308"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Xuexian Z, Ruidong W, Yuhan D, Qingwei L, Feng X, Hong R, Jun Z, Wei L. Safety and efficacy of DEB-TACE in combination with lenvatinib and camrelizumab for the treatment of unresectable hepatocellular carcinoma (uHCC): a two-centre retrospective study. Front Immunol. 2024; 15:1422784.","DOI":"10.3389\/fimmu.2024.1422784"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Yang H, Yang T, Qiu G, Liu J. Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study. J Hepatocell Carcinoma. 2023; 10:1435-1443.","DOI":"10.2147\/JHC.S423684"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Gon H, Kido M, Tanaka M, Kinoshita H, Komatsu S, Tsugawa D, Awazu M, Toyama H, Matsumoto I, Itoh T, Fukumoto T. Growth velocity of the portal vein tumor thrombus accelerated by its progression, alpha-fetoprotein level, and liver fibrosis stage in patients with hepatocellular carcinoma. Surgery. 2018; 164:1014-1022.","DOI":"10.1016\/j.surg.2018.06.025"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ji X, Zhang A, Duan X, Wang Q. Stereotactic body radiotherapy versus lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity matching score analysis. Radiat Oncol. 2024; 19:143.","DOI":"10.1186\/s13014-024-02527-1"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Hu Y, Zhou M, Tang J, <i>et al<\/i>. Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023; 29:4088-4097.","DOI":"10.1158\/1078-0432.CCR-22-2592"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, Kudo M, Ku Y, Sakamoto M, Nakashima O, Kaneko S, Kokudo N, Liver Cancer Study Group of J. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016; 65:938-943.","DOI":"10.1016\/j.jhep.2016.05.044"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (London, England). 2007; 370:1453-1457.","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Son SH, Jang HS, Lee H, Choi BO, Kang YN, Jang JW, Yoon SK, Kay CS. Determination of the \u03b1\/\u03b2 ratio for the normal liver on the basis of radiation-induced hepatic toxicities in patients with hepatocellular carcinoma. Radiation oncology (London, England). 2013; 8:61.","DOI":"10.1186\/1748-717X-8-61"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas dermo-sifiliograficas. 2021; 112:90-92.","DOI":"10.1016\/j.adengl.2019.05.021"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kudo M, Yamashita T, Finn RS, Galle PR, Ducreux M, Cheng AL, Tsuchiya K, Sakamoto N, Hige S, Take R, Yamada K, Nakagawa Y, Takahashi H, Ikeda M. Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150. Liver cancer. 2025; 1-16.","DOI":"10.1159\/000544981"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Hatanaka T, Kakizaki S, Hiraoka A, <i>et al<\/i>. Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients. Aliment Pharmacol Ther. 2024; 60:1361-1373.","DOI":"10.1111\/apt.18319"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Johnson PJ, Berhane S, Kagebayashi C, <i>et al<\/i>. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015; 33:550-558.","DOI":"10.1200\/JCO.2014.57.9151"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Qiu ZC, Dai JL, Zhang Y, Xie F, Yu Y, Leng SS, Wen TF, Li C. Association of the Number of Concurrent Metabolic Syndrome Risk Factors with Textbook Outcomes Following Liver Resection for Patients with Hepatocellular Carcinoma: A Multicenter Study. Ann Surg Oncol. 2025; 32:399-407.","DOI":"10.1245\/s10434-024-16343-0"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Clavien PA, Barkun J, de Oliveira ML, <i>et al<\/i>. The Clavien-Dindo classification of surgical complications: five-year experience. Annals of surgery. 2009; 250:187-196.","DOI":"10.1097\/SLA.0b013e3181b13ca2"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, Br\u00fa C, Rod\u00e9s J, Bruix J. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology (Baltimore, Md). 1999; 29:62-67.","DOI":"10.1002\/hep.510290145"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Kitao A, Zen Y, Matsui O, Gabata T, Nakanuma Y. Hepatocarcinogenesis: multistep changes of drainage vessels at CT during arterial portography and hepatic arteriography--radiologic-pathologic correlation. Radiology. 2009; 252:605-614.","DOI":"10.1148\/radiol.2522081414"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Shi B, Bian C, Li Z, Chen J, Yang D, Li Y, Hao X, Ping Y. Imaging findings of hepatocellular carcinoma with portal vein tumor thrombosis secondary to hepatic portal vein collateral circulation: a cross-sectional study. Journal of gastrointestinal oncology. 2023; 14:334-351.","DOI":"10.21037\/jgo-23-45"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Fujiwara K, Kondo T, Fujimoto K, <i>et al<\/i>. Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma. J Gastroenterol. 2024; 59:515-525.","DOI":"10.1007\/s00535-024-02097-9"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Jo HS, Park PJ, Yu YD, Choi YJ, Yu SH, Kim DS, Korean Liver Cancer A. Clinical significance of surgical resection for hepatocellular carcinoma with portal vein invasion: a nationwide cohort study. Hepatobiliary Surg Nutr. 2024; 13:814-823.","DOI":"10.21037\/hbsn-23-578"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Yang DL, Ye L, Zeng FJ, <i>et al<\/i>. Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages. Hepatology. 2025; 82:E40.","DOI":"10.1097\/HEP.0000000000001390"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Wu XK, Yang LF, Chen YF, Chen ZW, Lu H, Shen XY, Chi MH, Wang L, Zhang H, Chen JF, Huang JY, Zeng YY, Yan ML, Zhang ZB. Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study. EClinicalMedicine. 2024; 67:102367.","DOI":"10.1016\/j.eclinm.2023.102367"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Tang H, Zhang W, Cao J, <i>et al<\/i>. Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition). Biosci Trends. 2025; 18:505-524.","DOI":"10.5582\/bst.2024.01394"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Singal AG, Llovet JM, Yarchoan M, <i>et al<\/i>. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023; 78:1922-1965.","DOI":"10.1097\/HEP.0000000000000466"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Finn RS, Qin S, Ikeda M, <i>et al<\/i>. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020; 382:1894-1905.","DOI":"10.1056\/NEJMoa1915745"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Park JW, Kim YJ, Kim DY, Bae SH, Paik SW, Lee YJ, Kim HY, Lee HC, Han SY, Cheong JY, Kwon OS, Yeon JE, Kim BH, Hwang J. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial. Journal of hepatology. 2019; 70:684-691.","DOI":"10.1016\/j.jhep.2018.11.029"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Peng Z, Fan W, Zhu B, <i>et al<\/i>. Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023; 41:117-127.","DOI":"10.1200\/JCO.22.00392"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Xiang X, Lau WY, Wu ZY, Zhao C, Ma YL, Xiang BD, Zhu JY, Zhong JH, Li LQ. Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumor thrombus: A multicenter study. Eur J Surg Oncol. 2019; 45:1460-1467.","DOI":"10.1016\/j.ejso.2019.03.042"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Wang DX, Yang X, Lin JZ, Bai Y, Long JY, Yang XB, Seery S, Zhao HT. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China. World J Gastroenterol. 2020; 26:4465-4478.","DOI":"10.3748\/wjg.v26.i30.4465"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Chuma M, Uojima H, Hiraoka A, <i>et al<\/i>. Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis. Hepatol Res. 2021; 51:201-215.","DOI":"10.1111\/hepr.13592"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Zhu M, Liu Z, Chen S, Luo Z, Tu J, Qiao L, Wu J, Fan W, Peng Z. Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study. Hepatology. 2024; 80:807-815.","DOI":"10.1097\/HEP.0000000000000776"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Dawson LA, Winter KA, Knox JJ, <i>et al<\/i>. Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology\/RTOG 1112 Phase 3 Randomized Clinical Trial. JAMA oncology. 2025; 11:136-144.","DOI":"10.1001\/jamaoncol.2024.5403"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Sample JW. Beyond monotherapy: Combining radiotherapy with sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus. Hepatology (Baltimore, Md). 2024; 80:757-758.","DOI":"10.1097\/HEP.0000000000001041"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Li S, Li K, Wang K, <i>et al<\/i>. Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8(+) exhausted-like T cells. Nature communications. 2023; 14:7709.","DOI":"10.1038\/s41467-023-43462-1"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Wu TD, Madireddi S, de Almeida PE, <i>et al<\/i>. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature. 2020; 579:274-278.","DOI":"10.1038\/s41586-020-2056-8"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Lin X, Liu Z, Dong X, <i>et al<\/i>. Radiotherapy enhances the anti-tumor effect of CAR-NK cells for hepatocellular carcinoma. J Transl Med. 2024; 22:929.","DOI":"10.1186\/s12967-024-05724-4"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Zhang Y, Hong W, Zheng D, Li Z, Hu Y, Chen Y, Yang P, Zeng Z, Du S. Increased IFN-\u03b2 indicates better survival in hepatocellular carcinoma treated with radiotherapy. Clinical and experimental immunology. 2024; 218:188-198.","DOI":"10.1093\/cei\/uxae075"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Zhao CN, Chiang CL, Chiu WK, Chan SK, Li CJ, Chen WW, Zheng DY, Chen WQ, Ji R, Lo CM, Jabbour SK, Chan CA, Kong FS. Treatments of transarterial chemoembolization (TACE), stereotactic body radiotherapy (SBRT) and immunotherapy reshape the systemic tumor immune environment (STIE) in patients with unresectable hepatocellular carcinoma. Journal of the National Cancer Center. 2025; 5:38-49.","DOI":"10.1016\/j.jncc.2024.06.007"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Goh MJ, Park HC, Yu JI, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Sinn DH, Choi MS. Impact of Intrahepatic External Beam Radiotherapy in Advanced Hepatocellular Carcinoma Patients Treated with Tyrosine Kinase Inhibitors. Liver cancer. 2023; 12:467-478.","DOI":"10.1159\/000529635"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Llovet JM, Montal R, Villanueva A. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. Journal of hepatology. 2019; 70:1262-1277.","DOI":"10.1016\/j.jhep.2019.01.028"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Vaes RDW, Hendriks LEL, Vooijs M, De Ruysscher D. Biomarkers of Radiotherapy-Induced Immunogenic Cell Death. Cells. 2021; 10.","DOI":"10.3390\/cells10040930"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Jiao T, Tang H, Zhang W, Hu B, Wan T, Cao Y, Zhang Z, Wang Y, Cao J, Cui M, Lu S. Long-term survival and portal vein patency with novel PVTT surgery approach in advanced HCC patients with Vp3\/4 PVTT following combination therapy of TKIs and PD-1 inhibitors. BMC Surg. 2023; 23:384.","DOI":"10.1186\/s12893-023-02291-1"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Xiao Y, Li K, Zhao Y, Yang S, Yan J, Xiang C, Zeng J, Lu Q, Zhang C, Li G, Li G, Dong J. Efficacy of radiotherapy in combined treatment of hepatocellular carcinoma patients with portal vein tumor thrombus: a real-world study. BMC Surg. 2024; 24:54.","DOI":"10.1186\/s12893-024-02334-1"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Tan HY, Liu SQ, Zheng JL, Liu HY, Liu YH, Dai GH, Feng HG. Efficacy of radiotherapy combined with hepatic arterial infusion chemotherapy, TKI and ICI for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective cohort study. Abdom Radiol (NY). 2025; 50:1320-1329.","DOI":"10.1007\/s00261-024-04620-1"}],"container-title":["BioScience Trends"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/19\/4\/19_2025.01170\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T04:24:48Z","timestamp":1758342288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/19\/4\/19_2025.01170\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5582\/bst.2025.01170","relation":{},"ISSN":["1881-7815","1881-7823"],"issn-type":[{"value":"1881-7815","type":"print"},{"value":"1881-7823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,31]]},"article-number":"2025.01170"}}